Karyopharm Therapeutics, Inc.
(NASDAQ : KPTI)

( )
KPTI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.69%183.171.3%$509.31m
CELGCelgene Corporation
-0.84%92.411.3%$442.42m
ARRYArray BioPharma Inc.
-0.20%46.128.1%$426.45m
GILDGilead Sciences, Inc.
-2.63%66.680.9%$400.32m
BIIBBiogen Inc.
-0.92%238.071.3%$377.86m
ILMNIllumina, Inc.
-0.48%356.373.5%$303.03m
REGNRegeneron Pharmaceuticals, Inc.
-2.50%305.082.6%$243.93m
VRTXVertex Pharmaceuticals Incorporated
-1.38%177.661.9%$210.42m
ALXNAlexion Pharmaceuticals, Inc.
0.15%125.342.0%$206.43m
EXASExact Sciences Corporation
1.20%112.7924.1%$187.08m
AAgilent Technologies, Inc.
-0.46%72.181.6%$154.39m
BMRNBioMarin Pharmaceutical Inc.
-1.04%82.954.3%$124.74m
SRPTSarepta Therapeutics, Inc.
3.37%128.3414.7%$119.55m
INCYIncyte Corporation
-2.26%85.632.5%$112.69m
MRTXMirati Therapeutics Inc.
-2.09%100.012.5%$104.17m

Company Profile

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is engaged in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.